Patent Law | Expert Legal Commentary

June 16, 2011

In Re BP Lubricants USA, Inc.: The Federal Circuit Makes Bringing A False Marking Suit A Little Harder

In re BP Lubricants USA, Inc.

By Jeffrey J. Zuber and Sarah S. Brooks of Zuber & Taillieu

In Re BP Lubricants USA, Inc.: The Federal Circuit Makes Bringing A False Marking Suit A Little Harder

In an issue of first impression, the U.S. Court of Appeals for the Federal Circuit considered whether Fed. R. Civ. P. Rule 9(b)’s particularity requirement applies to false marking claims under §292. In In re BP Lubricants USA, Inc., 97 U.S.P.Q.2d 2025 (Fed. Cir. 2011), the Federal Circuit found that Rule 9(b)’s particularity requirement does apply to false marking claims and that a complaint alleging only conclusory allegations of intent is insufficient. This decision will certainly impact pending false marking cases, many of which may be dismissed after this decision for failure to comply with Rule 9(b).

BACKGROUND

BP Lubricants USA Inc. (“BP”) manufactures motor oil products and distributes them in a unique bottle for which BP received a design patent.  This patent expired on February 12, 2005, however BP continued to mark its bottles with the patent number. Thomas A. Simonian (“Simonian”), a patent attorney, filed a qui tam false patent marking suit against BP on behalf of the United States.

In the complaint, Simonian alleges that “BP knew or should have known that the patent expired” and that “BP is a sophisticated company and has experience applying for, and obtaining and litigating patents.”  The district court held that these allegations met the requirements of Rule 9(b).

BP argued that the intent to deceive element was insufficiently pled in the complaint and brought a motion to dismiss in the District Court.  The District Court denied BP’s motion to dismiss finding that the general allegations of the complaint were sufficient.

Does Fed. R. Civ. P. Rule 9(b) particularity requirement apply to false marking claims?

Before addressing the merits of BP’s argument that the complaint was insufficiently pled, the Federal Circuit considered whether Fed. R. Civ. P. Rule 9(b)’s particularity requirement applies to false marking claims.  The Federal Circuit found that because §292 “condemns fraudulent or false marking” and Rule 9(b) requires fraud to be pled with particularity, there is no reason to treat false marking claims any differently from other fraud-based claims.

Whether the Complaint Has been Pled with Particularity?

In considering whether the complaint was pled with sufficient particularity, the Federal Circuit noted that the complaint failed to allege any facts that showed that BP was aware of the patent’s expiration.  In fact, the Court noted that the District Court relied on the general statement that “BP knew or should have known” of the patent’s expiration.  The Court noted that this “bare allegation” was clearly not sufficient to survive a motion to dismiss.  Instead, for a false marking case, the plaintiff must provide some allegation from which one could infer that the defendant had knowledge that the patent expired.  Here, the plaintiff had not done so.

The Federal Circuit issued a writ of mandamus, directing the District Court to dismiss the complaint with leave to amend to correct the pleading requirements.

Conclusion

Although there has been a recent surge in false marking suits following the Federal Circuit’s decision in Stauffer v. Brooks Brothers, 2010 WL 3397419 (Fed. Cir. Aug. 31, 2010), this latest Federal Circuit decision will certainly result in many false marking cases being dismissed.  This decision requires particularly pleading facts relating to the Defendant’s knowledge that the patent in question had expired.  It is no longer sufficient to plead that the Defendant “should have known.”

About the Authors

Jeffrey J. Zuber is a Partner of Zuber & Taillieu, focusing on intellectual property litigation and arbitration.

Sarah S. Brooks is an Associate of Zuber & Taillieu, focusing on intellectual property litigation.

Image Credit: ©iStockphoto.com/koun

View a PDF of the judicial opinion

Connect on Linkedin®

Jeffrey J. Zuber
Sarah S. Brooks

Companies Mentioned

Also See:

Mayo v. Prometheus: The Supreme Court Reverses the Federal Circuit, Finding Prometheus' Patents Cover Laws of Nature and Therefore Ineligible Subject Matter

Celsis In Vitro, Inc. v. Cellzdirect, Inc.: Federal Circuit Disagrees on Obviousness Analysis Post-KSR

In re Ricoh Co., Ltd.: Federal Circuit Clarifies § 1920 Allowances for Prevailing Party to Charge Costs

Bosch v. Pylon: Federal Circuit Confirms Elimination of the Presumption of Irreparable Harm in Permanent Injunction Analysis

Therasense v. Becton: Federal Circuit Narrows Scope of Inequitable Conduct

Companies Mentioned

Patent Law

The following companies are mentioned in Patent Law Updates:

Boston Scientific Corp.

Microsoft Corp.

Samsung Electronics America, Inc.

Cordis Corp.

Boston Scientific Scimed, Inc.

U.S. Patent and Trademark Office

Stryker Corp.

Sanyo North America Corp.

LG Electronics, Inc.

Smith & Nephew, Inc.

Cohesive Technologies, Inc.

Waters Corp.

Swisa, Inc.

Egyptian Goddess, Inc.

Motorola, Inc.

Dror Swisa

Johnson & Johnson, Inc.

Target Corp.

Sears Holding Corp.

Prometheus Laboratories, Inc.

Mayo Collaborative Services d.b.a. Mayo Medical Laboratories

Kohl’s Department Stores, Inc.

K-Mart Corp.

J.C. Penney Company, Inc.

Audiovox Communications Corp.

Glamourmom LLC

McKesson Information Solutions, Inc.

Federated Department Stores

Bridge Medical, Inc.

Elizabeth Lange LLC d.b.a. Liz Lange Maternity

United States Patent and Trademark Office

Smithkline Beecham Corp. (d.b.a. GlaxoSmithKline, plc.)

SmithKline Beecham PLC

HT Window Fashion Corp.

SmithKline Beecham Corp. d.b.a GlaxoSmithKline

Scimed Life Systems Inc.

Ortho-McNeil Pharmaceutical, Inc.

Glaxo Group Limited d.b.a. GlaxoSmithKline

Mylan Pharmaceutical, Inc.

Ranbaxy, Inc.

Mylan Laboratories, Inc.

Nokia, Inc.

Teva Pharmaceuticals USA, Inc.

Stryker Sales Corp.

Stryker Orthopaedics

Howmedica Osteonics Corp.

Acumed, LLC

Quanta Computer, Inc.

Par Pharmaceutical Companies, Inc.

Robert Bosch LLC

Additional Resources

Patent Law

Further Reading in Patent Law

Other Recent Expert Legal Commentaries

More Patent Law Expert Legal Commentaries

Recent Summaries

More Patent Law Summaries